VivoSeq
Neurology

Partial Epilepsy

27

Pipeline Programs↗

0

Active Trials↗

21

Companies Involved↗

Partial Epilepsy is an emerging landscape with 27 programs across 21 companies. The most active players are Vertex Pharmaceuticals, Supernus Pharmaceuticals, Inc., Roche. 15 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

0/100

Mech. Concentration

32/100

Completion Rate

78/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

1 program

Phase 2Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

1 program

Phase 3Roche logo

Roche

1 program

Phase 3G

Glaxo Dba Glaxosmithkline

1 program

Phase 3Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.

2 programs

Phase 3GSK logo

GSK

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

23

clinical trials

Completed18 · 78%
Terminated4 · 17%
Withdrawn1 · 4%

Clinical Trials

Trial Activity

23 trials

Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy
Completed·GSK logoGSK·N/A·NCT01587339·6,498 enrolled
Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy
Completed·Eisai logoEisai·Phase 4·NCT01140867·121 enrolled
Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy
Completed·UUniversity of California, Davis·N/A·NCT00986310·2 enrolled
Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
Completed·Supernus Pharmaceuticals, Inc. logoSupernus Pharmaceuticals, Inc.·Phase 3·NCT00908349·214 enrolled
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy
Completed·BBial - Portela C S.A.·Phase 3·NCT00957372·253 enrolled
Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy
Completed·KKorea UCB Co., Ltd.·Phase 4·NCT01498822·353 enrolled
Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy
Completed·Vertex Pharmaceuticals logoVertex Pharmaceuticals·Phase 2·NCT01048255·60 enrolled
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
Completed·BBial - Portela C S.A.·Phase 3·NCT00957047·395 enrolled
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
Completed·SSK Life Science, Inc.·Phase 2·NCT00228969
Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy
Completed·UCB logoUCB·Phase 4·NCT00630357·14 enrolled
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
Completed·Sumitomo Pharma America, Inc. logoSumitomo Pharma America, Inc.·Phase 3·NCT00866775·193 enrolled
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
Completed·GSK logoGSK·Phase 3·NCT00355082·226 enrolled
Phase II BGG492 Capsule Extension for Partial Epilepsy
Completed·Novartis logoNovartis·Phase 2·NCT01338805·56 enrolled
A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy
Completed·Eisai logoEisai·Phase 3·NCT00477295·583 enrolled
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
Completed·Pfizer logoPfizer·Phase 2·NCT00141414·82 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)